Inner Ear Organoid Maturation Timing for Higher Hair Cell Yield
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for producing inner ear organoids result in low efficiency and a small number of hair cells, limiting their suitability for drug screening and disease modeling.
Innovation Solution
A method involving the use of a gamma secretase inhibitor and a Wnt signaling activator during the maturation stage of inner ear organoid production, specifically treating cells with DAPT and CHIR-99021 for 5-7 days after day 25 for mESCs and 80-90 days for hiPSCs, to enhance hair cell differentiation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If a three-dimensional culture protocol is used for inner ear organoid production, then organoid formation is achieved, but production efficiency is very low and hair cell number is very small (about 1% of total cells)
Solution Approach 1:
The patent applies parameter changes by optimizing the timing and concentration of gamma secretase inhibitor and Wnt signaling activator treatment during the maturation stage. Specifically, treating with gamma secretase inhibitor from day 25-34 and Wnt signaling activator from day 28-37 significantly increases hair cell differentiation, achieving hair cells comprising about 10-20% of total cells, thereby resolving the contradiction between production efficiency and hair cell quantity
Solution Approach 2:
The patent implements preliminary action by pre-treating organoids with gamma secretase inhibitor and Wnt signaling activator during the maturation stage before final hair cell differentiation is complete. This preliminary intervention ensures that hair cell differentiation pathways are activated early, maximizing hair cell generation and improving overall production efficiency
2Quantity of substance
If gamma secretase inhibitor and Wnt signaling activator are treated during maturation stage, then hair cell differentiation is significantly improved, but treatment timing and protocol complexity increase
Solution Approach 1:
The patent resolves protocol complexity by defining specific parameter ranges: gamma secretase inhibitor treatment from day 25-34 and Wnt signaling activator treatment from day 28-37. These optimized parameters simplify the protocol by establishing clear treatment windows, making the complex differentiation process more manageable and reproducible while maintaining high hair cell differentiation efficiency
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method significantly increases the number of hair cells in the organoids, improving efficiency for drug screening and disease modeling related to hearing loss.
Implementation Method 1
Gamma secretase (t-secretase) is a hydrolytic enzyme that cleaves the transmembrane site of Notch, and it liberates the Notch intracellular domain (NICD) into cells. Therefore, gamma secretase inhibitors can induce hair cells from support cells by reducing the expression level of NICD.
Implementation Method 2
Wnt signaling is known to be important for sensory progenitor cell proliferation and hair cell differentiation in the embryonic stage by stabilizing β-catenin due to the inhibition of GSK-3, activity, which enters the nucleus and acts as a Tcf/Lef transcription factor to activate target genes.
Data Source
AI summary
The present invention relates to a method for producing inner ear organoids having improved hair cell differentiation ability, and the inner ear organoids produced according to the same. The present invention is based on the discovery that treatment with a gamma secretase inhibitor and a Wnt signaling activator during the production of inner ear organoids can promote the differentiation of hair cells, and provides the timing of the treatment with a gamma secretase inhibitor and a Wnt signaling activator at which the amount of hair cells in the inner ear organoids can be maximized. The present technology may be used as a method for increasing the production efficiency of inner ear organoids to be applied in the field of hearing loss treatment.